Ed Miner, MD, FACC
Utah, Chapter President
ACC Governor, Utah

Rockies Chapter Meeting Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!. For more information and to register, please visit: ACC Rockies Chapter Meeting 2025

ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS Latest in Cardiology from ACC.org

  • GoFreshRx: Home-Delivered DASH Groceries Improve BP and LDL-C in Black Adults With Hypertension
    A structured grocery home-delivery program aligned with the DASH (Dietary Approaches to Stop Hypertension) diet along with dietitian counseling significantly reduced systolic blood pressure (SBP) and LDL-C among Black adults with hypertension living in a food desert compared with a grocery stipend and basic dietary guidance, according to results from the GoFreshRx trial, presented during […]
  • Ez-PAVE: Hitting Lower LDL-C Target Reduces Major CV Events
    Lowering LDL-C to
  • VESALIUS-CV: Evolocumab Reduces CV Risk in Diabetic Patients Without ASCVD
    The PCSK9 inhibitor evolocumab reduced the risk of a first major cardiovascular event in patients with diabetes without known significant atherosclerosis, according to a prespecified subgroup analysis of the VESALIUS-CV trial, presented during a Late-Breaking Clinical Trial session at ACC.26 in New Orleans and simultaneously published in JAMA.
  • KARDINAL: Tonlamarsen Reduces Plasma AGT, Not SBP
    A monthly dose of the novel drug tonlamarsen significantly reduced plasma angiotensinogen (AGT) levels compared to a single dose of the drug followed by a placebo, but no reduction in systolic blood pressure (SBP) was observed in patients with uncontrolled hypertension, according to the phase 2 KARDINAL trial presented during a Late-Breaking Clinical Trial session […]
  • CHAMPION-AF: Left Atrial Appendage Closure vs. Anticoagulation For AFib
    Device-based left atrial appendage (LAA) closure was comparable to non-vitamin K antagonist oral anticoagulant (NOAC) therapy in reducing the combined rate of death from cardiovascular causes, stroke, or systemic embolism at three years in patients with atrial fibrillation (AFib) who were candidates for anticoagulation, based on findings from the CHAMPION-AF trial presented at ACC.26 and […]